Center for Scientific Review; Notice of Closed Meetings, 61634-61635 [2019-24614]
Download as PDF
<![CDATA[
61634
Federal Register / Vol. 84, No. 219 / Wednesday, November 13, 2019 / Notices
The public meeting will be
held at the Bethesda North Marriott
Hotel and Conference Center, 5701
Marinelli Rd., Rockville, MD 20852;
301–822–9200. The meeting will also be
held online via webcast. To pre-register
to attend the meeting, please visit the
registration website at https://
events.kauffmaninc.com/events/nccc5/.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Linda Harris, Designated Federal
Officer, National Clinical Care
Commission, U.S. Department of Health
and Human Services, Office of the
Assistant Secretary for Health, Office of
Disease Prevention and Health
Promotion, 1101 Wootton Parkway,
Suite 420, Rockville, MD 20852. Email:
OHQ@hhs.gov.
The
National Clinical Care Commission Act
(Pub. L. 115–80) requires the HHS
Secretary to establish the National
Clinical Care Commission. The
Commission consists of representatives
of specific federal agencies and nonfederal individuals and entities who
represent diverse disciplines and views.
The Commission will evaluate and
make recommendations to the HHS
Secretary and Congress regarding
improvements to the coordination and
leveraging of federal programs related to
awareness and clinical care for complex
metabolic or autoimmune diseases that
result from issues related to insulin that
represent a significant disease burden in
the United States, which may include
complications due to such diseases.
During this fifth meeting, the
Commission will hear from informants
from selected federal agencies about
programs related to diabetes prevention,
treatment and discuss potential topics
for the Commission’s final report. The
final meeting agenda will be available
prior to the meeting at https://
health.gov/hcq/national-clinical-carecommission.asp.
Public Participation at Meeting: The
Commission invites public comment on
issues related to the Commission’s
charge either in-person at the meeting or
in writing. In-person attendees who
plan to provide oral comments at the
Commission meeting during a
designated time must submit their
comments to OHQ@hhs.gov on or before
November 15, 2019 and must check-in
on-site. To accommodate as many
individuals as possible, the time for
each comment will be limited to three
minutes. If more requests are received
than can be accommodated, speakers
will be randomly selected. The nature of
the comments will not be considered in
making this selection.
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
17:23 Nov 12, 2019
Jkt 250001
Written comments are welcome
throughout the entire development
process of the Commission’s
recommendation and may be emailed to
OHQ@hhs.gov, or by mail to the
following address: Public Commentary,
National Clinical Care Commission,
1101 Wootton Parkway, Suite 420,
Rockville, MD 20852. Written comments
should not exceed three pages in length.
Individuals who need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should indicate the
special accommodation when
registering online or by notifying
Jennifer Gillissen at jennifer.gillissen@
kauffmaninc.com by November 15.
Authority: The National Clinical Care
Commission is required under the
National Clinical Care Commission Act
(Pub. L. 115–80). The Commission is
governed by provisions of the Federal
Advisory Committee Act (FACA), Public
Law 92–463, as amended (5 U.S.C.,
App.) which sets forth standards for the
formation and use of federal advisory
committees.
Dated: November 5, 2019.
Donald Wright,
Deputy Assistant Secretary for Health,
Disease Prevention and Health Promotion.
[FR Doc. 2019–24636 Filed 11–12–19; 8:45 am]
BILLING CODE 4150–32–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Cancer Health Disparities.
Date: December 5–6, 2019.
Time: 7:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW,
Washington, DC 20015.
Contact Person: Nywana Sizemore, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6204,
MSC 7804, Bethesda, MD 20892, (301) 435–
1718, sizemoren@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cardiovascular Sciences.
Date: December 5–6, 2019.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kimm Hamann, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4118A,
MSC 7814, Bethesda, MD 20892, (301) 435–
5575, hamannkj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: AIDS and AIDS Related Research.
Date: December 5–6, 2019.
Time: 9:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jingsheng Tuo, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5207,
Bethesda, MD 20892, (301) 451–8754, tuoj@
nei.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Psycho/Neuropathology Lifespan
Development.
Date: December 5, 2019.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Elia E. Ortenberg, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3108,
Bethesda, MD 20892, (301) 827–7189,
femiaee@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Neurodegeneration, Myelination
and Glia.
Date: December 5, 2019.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Mary Custer, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4148,
MSC 7850, Bethesda, MD 20892, (301) 435–
1164, custerm@csr.nih.gov.
E:\FR\FM\13NON1.SGM
13NON1
Federal Register / Vol. 84, No. 219 / Wednesday, November 13, 2019 / Notices
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Vascular
and Hematology Research Enhancement
Award Application Review.
Date: December 5, 2019.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Natalia Komissarova,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5207,
MSC 7846, Bethesda, MD 20892, (301) 435–
1206, komissar@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Topics in Toxicology and
Pharmacology.
Date: December 5, 2019.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Atul Sahai, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2188,
MSC 7818, Bethesda, MD 20892, (301) 435–
1198 sahaia@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 6, 2019.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–24614 Filed 11–12–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Notice of Meeting
Pursuant to Public Law 92–463,
notice is hereby given that the
Substance Abuse and Mental Health
Services Administration’s (SAMHSA)
Center for Substance Abuse Prevention’s
(CSAP) Drug Testing Advisory Board
(DTAB) will convene via in person and
web conference on December 3rd, 2019,
from 9:30 a.m. EST to 4:30 p.m. EST,
and December 4th, 2019, from 9:00 a.m.
EST to 4:00 p.m. EST.
The board will meet in open-session
in-person on December 3rd, 2019, from
9:30 a.m. EST to 4:30 p.m. EST to
discuss the Mandatory Guidelines for
VerDate Sep<11>2014
17:23 Nov 12, 2019
Jkt 250001
Federal Workplace Drug Testing
Programs (urine and oral fluid
specimens) with updates from the
Department of Transportation, Nuclear
Regulatory Commission, and the
Department of Defense. Other
discussion topics include the impact of
cannabis laws on drug testing and
standard variables. There will be
additional presentations from the
Division of Workplace Programs’ staff
on urine, oral fluid, hair Mandatory
Guidelines; and the electronic chain of
custody. The board will meet in closedsession in-person on December 4th,
2019, from 9:00 a.m. EST to 4:00 p.m.
EST to discuss confidential issues
surrounding the proposed Mandatory
Guidelines for Federal Workplace Drug
Testing Programs (hair), HHS drug panel
review, preliminary and unpublished
studies from the Johns Hopkins
University Behavioral Pharmacology
Research Unit (BPRU);
recommendations to the Assistant
Secretary for Mental Health and
Substance Use regarding additional
drugs (fentanyl and methadone) that
may be tested for in the future, and
lastly, program financials. Therefore, the
December 4th, 2019, from 9:00 a.m. EST
to 4:00 p.m. EST, meeting is closed to
the public, as determined by the
Assistant Secretary for Mental Health
and Substance Use, SAMHSA, in
accordance with 5 U.S.C. 552b(c)(4) and
(9)(B), and 5 U.S.C. App. 2, Section
10(d).
Meeting registration information can
be completed at https://
snacregister.samhsa.gov/
MeetingList.aspx. Web conference and
call information will be sent after
completing registration. Meeting
information and a roster of DTAB
members may be obtained by accessing
the SAMHSA Advisory Committees
website, https://www.samhsa.gov/
about-us/advisory-councils/meetings or
by contacting the Designated Federal
Officer, Jennifer Fan.
Committee Name: Substance Abuse
and Mental Health Services
Administration, Center for Substance
Abuse Prevention, Drug Testing
Advisory Board.
Dates/Time/Type: December 3, 2019,
from 9:30 a.m. to 4:30 p.m. EST: OPEN.
December 4, 2019, from 9:00 a.m. to
4:00 p.m. EST: CLOSED.
Place: Substance Abuse and Mental
Health Services Administration, 5th
Floor Pavilion A, B, 5600 Fishers Lane,
Rockville, MD 20857.
Contact: Jennifer Fan, Senior
Pharmacist, Center for Substance Abuse
Prevention, 5600 Fishers Lane, Room
16N06D, Rockville, Maryland 20857,
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
61635
Telephone: (240) 276–1759, email:
jennifer.fan@samhsa.hhs.gov.
Anastasia Marie Donovan,
Policy Anayst.
[FR Doc. 2019–24649 Filed 11–12–19; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Notice of Subcommittee Meetings for
the Interdepartmental Serious Mental
Illness Coordinating Committee
(ISMICC)
Substance Abuse and Mental
Health Services Administration,
Department of Health and Human
Services.
AGENCY:
Notice of subcommittee
meetings (virtual).
ACTION:
The Secretary of Health and
Human Services (Secretary) announces
subcommittee meetings of the
Interdepartmental Serious Mental
Illness Coordinating Committee
(ISMICC). The meetings are open to the
public and can be accessed via
telephone only. Agenda with call-in
information will be posted on the
SAMHSA website prior to the meetings
at: https://www.samhsa.gov/about-us/
advisory-councils/meetings. The
meetings will include information on
the following focus areas: Data, Access,
Treatment and Recovery, Justice, and
Finance.
Committee Name: Interdepartmental
Serious Mental Illness Coordinating
Committee (subcommittee meetings).
Date/Time/Type:
December 4, 2019/9:00 a.m.–10:30 a.m.
(EST)/OPEN/Focus Area 3: Treatment
and Recovery
December 4, 2019/10:45 a.m.–12:15 p.m.
(EST)/OPEN/Focus Area 1: Data
December 4, 2019/10:45 a.m.–12:15 p.m.
(EST)/OPEN/Focus Area 4: Justice
December 4, 2019/1:00 p.m.–2:30 p.m.
(EST)/OPEN/Focus Area 2: Access
and Engagement
December 4, 2019/1:00 p.m.–2:30 p.m.
(EST)/OPEN/Focus Area 5: Finance
ADDRESSES: The meetings will be held
virtually.
Substantive meeting information and
a roster of Committee members is
available at the Committee’s website
https://www.samhsa.gov/about-us/
advisory-councils/smi-committee.
SUPPLEMENTARY INFORMATION:
SUMMARY:
E:\FR\FM\13NON1.SGM
13NON1
]]>Agencies
[Federal Register Volume 84, Number 219 (Wednesday, November 13, 2019)]
[Notices]
[Pages 61634-61635]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-24614]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR Panel: Cancer Health Disparities.
Date: December 5-6, 2019.
Time: 7:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military
Road NW, Washington, DC 20015.
Contact Person: Nywana Sizemore, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6204, MSC 7804, Bethesda, MD
20892, (301) 435-1718, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Cardiovascular Sciences.
Date: December 5-6, 2019.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kimm Hamann, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4118A, MSC 7814, Bethesda, MD 20892, (301)
435-5575, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: AIDS and AIDS Related Research.
Date: December 5-6, 2019.
Time: 9:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jingsheng Tuo, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5207, Bethesda, MD 20892, (301) 451-8754,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: Psycho/Neuropathology Lifespan Development.
Date: December 5, 2019.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Elia E. Ortenberg, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3108, Bethesda, MD 20892, (301)
827-7189, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Neurodegeneration, Myelination and Glia.
Date: December 5, 2019.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Mary Custer, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4148, MSC 7850, Bethesda, MD 20892, (301) 435-
1164, [email protected].
[[Page 61635]]
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Vascular and Hematology Research Enhancement Award
Application Review.
Date: December 5, 2019.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Natalia Komissarova, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5207, MSC 7846, Bethesda, MD
20892, (301) 435-1206, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Topics in Toxicology and Pharmacology.
Date: December 5, 2019.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Atul Sahai, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 2188, MSC 7818, Bethesda, MD 20892, (301) 435-
1198 [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: November 6, 2019.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-24614 Filed 11-12-19; 8:45 am]
BILLING CODE 4140-01-P
